Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

UTUrbain Tauveron-JalenquesETEmmanuelle TavernierNMNatacha Mauz

Discussion

Loading...

Member takes

Overview

Analysis reveals shorter venetoclax exposure lowers overall responses in AML patients, suggesting longer courses may be beneficial.

Key Points

  • To compare the efficacy and safety of 7-day versus standard venetoclax exposure in treating acute myeloid leukemia (AML).
  • Retrospective analysis of data from the VENAURA registry involving 775 patients from 10 centers.
  • Comparison of outcomes between 52 patients who received 7 days of venetoclax and 202 patients on standard regimens (≥21 days).
  • Assessment of overall response rates defined by remission criteria from VIALE-A trial.
  • CRc was significantly lower in the short-course group (40%) compared to the standard group (57%).
  • Median overall survival was shorter in the short-course group (6 months) compared to standard (13 months).
  • Short-course regimen associated with higher early mortality rates (21% at 30 days) compared to standard (5%).

Cite This Study

Tauveron-Jalenques et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da65https://doi.org/10.1182/blood-2025-3398
View Full Paper
Ask AI
Bookmark
Share